Carboplatin AUC-5

Phase 2Small molecule

Merck & Co.

Carboplatin AUC-5 is one of 264 small molecule programs targeting Ovarian Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

263

Competitors

Pipeline

Status by Indication[3][1]

Indication

Ovarian CancerNot yet recruiting

Solid TumorRecruiting

Advanced Solid TumorsCompleted

ChemotherapyNot yet recruiting

TreatmentRecruiting

IvonescimabRecruiting

Patients With Advanced Solid TumorsActive, not recruiting

MicrobiotaNot yet recruiting

Pleural MesotheliomasRecruiting

Combination TherapyNot yet recruiting

Ovarian CancerPhase 2

Not yet recruiting

Solid TumorPreclinical

Recruiting

Advanced Solid TumorsPhase 1

Completed

ChemotherapyPhase 2

Not yet recruiting

TreatmentPhase 1

Recruiting

IvonescimabPhase 2

Recruiting

Patients With Advanced Solid TumorsPhase 2

Active, not recruiting

MicrobiotaPhase 2

Not yet recruiting

Pleural MesotheliomasPhase 2

Recruiting

Combination TherapyPhase 2

Not yet recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Carboplatin AUC-5

Merck & Co.

Phase 2

1 2

Yervoy

Bristol-Myers Squibb

Preclinical

3 3

Fludara

Sanofi

Preclinical

2 4

DATROWAY

Daiichi Sankyo

Preclinical

1 5

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

3 6

Augtyro

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

2 7

Navmi

SSummit Therapeutics

Preclinical

1 8

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 9

Ifinatamab Deruxtecan

Daiichi Sankyo

Preclinical

1 10

Tulmimetostat

Novartis

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Not yet recruiting

Ovarian Cancer

NCT07432594

Q2 2028

Phase 2Recruiting

Ivonescimab

NCT07245446

Q3 2028

Phase 2Not yet recruiting

Combination Therapy

NCT07448922

Q1 2029

Phase 1/2Active, not recruiting

Patients With Advanced Solid Tumors

NCT06771622

Clinical

Trials by Indication[1]

Efficacy and Safety2 trials

Predictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC

Unknown status·HHao Long·Phase 2·NCT05244837·100 enrolled

Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy

Terminated·UUniversity of Massachusetts, Worcester·Phase 1·NCT00424840·12 enrolled

Advanced Solid Tumors2 trials

Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT02862457·34 enrolled

A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors

Active, not recruiting·CCullinan Therapeutics Inc.·Phase 1·NCT05117476·440 enrolled

Non-Small Cell Lung Cancer1 trial

A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

Completed· Eli Lilly logo

Eli Lilly·Phase 2·NCT01160744·280 enrolled

Small Cell Lung Cancer1 trial

Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients

Completed·SSpanish Lung Cancer Group·Phase 2·NCT03081689·46 enrolled

Microbiota1 trial

Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)

Not yet recruiting·FFundación GECP·Phase 2·NCT07247786·68 enrolled

10 more indications

Pleural Mesothelioma1 trial

Nivolumab With Chemotherapy in Pleural Mesothelioma After Surgery

Completed·IInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest·Phase 2·NCT04177953·92 enrolled

Treatment1 trial

A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC

Recruiting·XXijing Hospital·Phase 1·NCT07178171·30 enrolled

Ovarian Cancer1 trial

Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer

Not yet recruiting·—·Phase 2·NCT07432594·82 enrolled

Chemotherapy1 trial

Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC

Not yet recruiting·YYang Hong·Phase 2·NCT07309952·28 enrolled

Combination Therapy1 trial

A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors

Not yet recruiting·SSichuan Kelun Pharmaceutical Research Institute Co., Ltd.·Phase 2·NCT07448922·290 enrolled

Ivonescimab1 trial

A Study of Ivonescimab in First-Line ES-SCLC

Recruiting·AAkeso·Phase 2·NCT07245446·180 enrolled

Patients With Advanced Solid Tumors1 trial

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Active, not recruiting·FFBD Biologics Limited·Phase 1/2·NCT06771622·500 enrolled

Metastatic Non-squamous Non Small Cell Lung Cancer1 trial

A Ph2, Randomized, Blinded, Placebo-Controlled Trial Investigating the Efficacy and Safety of Visugromab Versus Placebo, in Combination With Pembrolizumab, Pemetrexed, and Carboplatin, in 1L Treatment of Participants With Metastatic NSCLC (GDFATHER-NSCLC-01)

Recruiting·CCatalYm GmbH·Phase 2·NCT07098988·107 enrolled

Pleural Mesotheliomas1 trial

A Non-Comparative Phase IIR Trial Assessing Fianlimab Plus Cemiplimab Plus Pemetrexed-Platinum Chemotherapy or Cemiplimab Plus Pemetrexed-Platinum Chemotherapy for Treatment-Naive Pleural Mesothelioma (PM) Patients

Recruiting·IIntergroupe Francophone de Cancerologie Thoracique·Phase 2·NCT07234058·126 enrolled

Solid Tumor1 trial

An Open-Label, Multicenter, First-in-Human, Dose-Escalation, Multicohort, Phase 1/2 Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors

Recruiting·IInhibrx Biosciences, Inc·Preclinical·NCT04198766·340 enrolled

Sources

References

[1]
ClinicalTrials.gov — 17 trial records for Carboplatin AUC-5. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Carboplatin AUC-5 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Carboplatin AUC-5. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

Carboplatin AUC-5

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q2 2028

Q3 2028

Q1 2029

Trials by Indication[1]

Efficacy and Safety2 trials

Advanced Solid Tumors2 trials

Non-Small Cell Lung Cancer1 trial

Small Cell Lung Cancer1 trial

Microbiota1 trial

Pleural Mesothelioma1 trial

Treatment1 trial

Ovarian Cancer1 trial

Chemotherapy1 trial

Combination Therapy1 trial

Ivonescimab1 trial

Patients With Advanced Solid Tumors1 trial

Metastatic Non-squamous Non Small Cell Lung Cancer1 trial

Pleural Mesotheliomas1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News